BNP Paribas reiterated their underperform rating on shares of GlaxoSmithKline plc (LON:GSK) in a research report sent to investors on Friday. The brokerage currently has a GBX 1,520 ($19.84) price objective on the stock.
GSK has been the subject of a number of other research reports. Societe Generale downgraded shares of GlaxoSmithKline plc to a sell rating and lifted their target price for the stock from GBX 1,300 ($16.97) to GBX 1,320 ($17.23) in a research report on Thursday, September 8th. JPMorgan Chase & Co. reiterated a neutral rating and set a GBX 1,900 ($24.80) price target on shares of GlaxoSmithKline plc in a research note on Tuesday, August 23rd. Liberum Capital reiterated a buy rating and set a GBX 1,900 ($24.80) price target on shares of GlaxoSmithKline plc in a research note on Tuesday, September 20th. Deutsche Bank AG reiterated a hold rating and set a GBX 1,800 ($23.50) price target on shares of GlaxoSmithKline plc in a research note on Friday, September 2nd. Finally, Beaufort Securities reiterated a buy rating on shares of GlaxoSmithKline plc in a research note on Friday, September 16th. Three research analysts have rated the stock with a sell rating, sixteen have given a hold rating and eight have assigned a buy rating to the company’s stock. GlaxoSmithKline plc has an average rating of Hold and an average target price of GBX 1,676.44 ($21.88).
GlaxoSmithKline plc (LON:GSK) traded up 1.13% on Friday, reaching GBX 1661.50. The company had a trading volume of 3,508,581 shares. The stock’s market capitalization is GBX 80.77 billion. GlaxoSmithKline plc has a 12-month low of GBX 1,261.50 and a 12-month high of GBX 1,716.50. The stock’s 50 day moving average price is GBX 1,645.84 and its 200-day moving average price is GBX 1,542.41.
The business also recently announced a dividend, which will be paid on Thursday, October 13th. Shareholders of record on Thursday, August 11th will be paid a GBX 19 ($0.25) dividend. The ex-dividend date of this dividend is Thursday, August 11th. This represents a yield of 1.12%.
In related news, insider Slaoui,Moncef bought 28 shares of the company’s stock in a transaction on Friday, August 12th. The shares were acquired at an average cost of GBX 2,208 ($28.82) per share, for a total transaction of £618.24 ($807.00). Also, insider Witty,Sir Andrew P sold 10,000 shares of the company’s stock in a transaction dated Wednesday, July 27th. The stock was sold at an average price of GBX 1,693 ($22.10), for a total transaction of £169,300 ($220,989.43).
GlaxoSmithKline plc Company Profile
GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.
Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.